Gatifloxacin (mesylate)

Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) [1]. Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.

Product Specifications

CAS Number

[316819-28-0]

Product Name Alternative

AM-1155 (mesylate) ; BMS-206584 (mesylate) ; PD135432 (mesylate)

UNSPSC

12352005

Target

Antibiotic; Bacterial; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/gatifloxacin-mesylate.html

Solubility

10 mM in DMSO

Smiles

CC1NCCN(C2=C(F)C=C3C(N(C4CC4)C=C(C(O)=O)C3=O)=C2OC)C1.O=S(C)(O)=O

Molecular Formula

C20H26FN3O7S

Molecular Weight

471.50

References & Citations

[1]Takei M, et al. Inhibitory activities of Gatifloxacin mesylate (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.Antimicrob Agents Chemother. 1998 Oct;42 (10) :2678-81.|[2]Fukuda H, et al. Antibacterial activity of Gatifloxacin mesylate (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Aug;42 (8) :1917-22.|[3]Yamada C, et al. Gatifloxacin mesylate acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur J Pharmacol. 2006 Dec 28;553 (1-3) :67-72. Epub 2006 Sep 28.|[4]Daw-Garza A, et al. In vivo therapeutic effect of Gatifloxacin mesylate on BALB/c mice infected with Nocardia brasiliensis.Antimicrob Agents Chemother. 2008 Apr;52 (4) :1549-50.